Earlybird, Sofinnova back Swiss start-up Haya in move toward clinic: Finance Report

Switzerland-based Haya will move its lead long non-coding RNA program into this clinic with a new $65 million series A round, designed to deliver proof-of-concept data in patients with heart failure.

For co-leader Earlybird Venture Capital, the deal is the first for a company that is still several months away from the clinic, the firm’s Rabab Nasrallah told BioCentury. Typically, Earlybird’s therapeutics investments go to start-ups that have either begun clinical testing or are weeks away from a first-in-human study...